Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.80 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.62 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.56 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.56 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.34 |
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.34 |
| ▸ | F2 | P00734 | 3/20 | 0.33 |
| ▸ | F10 | P00742 | 3/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14801644 | 1.00 | KCNH2 (0.80) | KCNH2PTGS1SLC6A2SLC6A4CACNA1C | |
| SCHEMBL1228132 | 0.97 | KCNH2 (0.75) | KCNH2PTGS1SLC6A2SLC6A4CACNA1C | |
| SCHEMBL16625078 | 0.92 | KCNH2 (0.69) | KCNH2PTGS1SLC6A2SLC6A4CACNA1C | |
| SCHEMBL19704657 | 0.91 | KCNH2 (0.67) | KCNH2PTGS1SLC6A2SLC6A4CACNA1C | |
| SCHEMBL18031088 | 0.91 | KCNH2 (0.67) | KCNH2PTGS1SLC6A2SLC6A4CACNA1C | |
| SCHEMBL16624931 | 0.90 | KCNH2 (0.66) | KCNH2PTGS1SLC6A2SLC6A4CACNA1C | |
| SCHEMBL19704647 | 0.90 | KCNH2 (0.66) | KCNH2PTGS1SLC6A2SLC6A4CACNA1C | |
| SCHEMBL1227151 | 0.90 | KCNH2 (0.66) | KCNH2PTGS1SLC6A2SLC6A4CACNA1C | |
| SCHEMBL1227152 | 0.89 | KCNH2 (0.76) | KCNH2PTGS1SLC6A2SLC6A4CACNA1C | |
| SCHEMBL3195951 | 0.89 | KCNH2 (0.76) | KCNH2PTGS1SLC6A2SLC6A4CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576567-A1 | NITROIMIDAZOLE DERIVATIVES | GE Healthcare UK Limited (GB) | 2013-04-10 | — | — | EP | disclosed |
| US-20130078185-A1 | NITROIMIDAZOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2013-03-28 | — | — | US | disclosed |
| US-20130078185-A1 | NITROIMIDAZOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2013-03-28 | — | — | US | disclosed |
| US-20130078185-A1 | NITROIMIDAZOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2013-03-28 | — | — | US | disclosed |
| WO-2011151320-A1 | NITROIMIDAZOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011151320-A1 | NITROIMIDAZOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2011-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130078185-A1 | NITROIMIDAZOLE DERIVATIVES | MAVS, MT-ND4, MT-ND5 | KCNH2 2939/4885PTGS1 1128/4885SLC6A2 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.